Long-Term Effectiveness of Esaxerenone in Diabetic Kidney Disease: A Comprehensive Review

Abstract

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD) worldwide, prompting intensified research into novel therapies that can slow disease progression and improve outcomes. Esaxerenone, a selective non-steroidal mineralocorticoid receptor antagonist (MRA), has garnered interest for its renoprotective effects and favorable safety profile. This review critically evaluates the long-term effectiveness of esaxerenone in DKD, examining evidence from recent clinical trials, real-world studies, and mechanistic insights, with a focus on clinical relevance for nephrologists and endocrinologists.

Introduction

Diabetic kidney disease is a microvascular complication of diabetes mellitus, marked by persistent albuminuria, declining glomerular filtration rate (GFR), and increased cardiovascular morbidity. Despite advances in glycemic control and renin-angiotensin-aldosterone system (RAAS) blockade, residual risk for DKD progression remains high. Esaxerenone, an emerging selective MRA, offers a novel approach to renoprotection by attenuating aldosterone-induced inflammation and fibrosis. This article synthesizes recent literature to provide clinicians with an evidence-based understanding of esaxerenone’s role in the long-term management of DKD.

Epidemiology / Disease Burden

DKD affects approximately 30–40% of individuals with type 1 or type 2 diabetes, representing the most prevalent cause of ESRD globally. The rising incidence of diabetes, especially in aging populations, has amplified the burden on healthcare systems. DKD is associated with heightened cardiovascular risk, increased hospitalization, and substantial healthcare costs. The progressive nature of DKD underscores the unmet need for effective, durable therapies that can delay or prevent renal function decline.

Pathophysiology

Chronic hyperglycemia initiates a cascade of pathophysiological events in the kidney, including glomerular hypertension, oxidative stress, and activation of the RAAS. Aldosterone, via mineralocorticoid receptors, promotes sodium retention, vascular inflammation, and fibrosis, contributing to glomerulosclerosis and tubulointerstitial injury. Esaxerenone selectively inhibits mineralocorticoid receptors in renal and cardiovascular tissues, thereby mitigating downstream inflammatory and fibrotic processes. Its advantageous selectivity profile reduces off-target effects compared to traditional steroidal MRAs.

Risk Factors

Key risk factors for DKD progression include poor glycemic control, hypertension, dyslipidemia, smoking, genetic predisposition, and persistent proteinuria. Duration of diabetes, presence of retinopathy, and baseline kidney function also modulate risk. Inadequate inhibition of the RAAS, aldosterone breakthrough, and inadequate blood pressure control further accelerate renal decline. Recognizing and modifying these risk factors is essential for optimal management of DKD.

Clinical Features

DKD typically presents with microalbuminuria, gradually progressing to macroalbuminuria, declining GFR, and ultimately ESRD. Clinical manifestations may include edema, hypertension, and features of chronic kidney disease such as anemia and electrolyte disturbances. Subclinical cardiovascular disease is common in DKD patients, highlighting the need for integrated management strategies targeting both renal and cardiac outcomes.

Diagnosis

The diagnosis of DKD relies on the detection of persistent albuminuria (>30 mg/g creatinine) and/or reduced GFR (<60 mL/min/1.73m²) in patients with longstanding diabetes, after excluding other primary kidney diseases. Assessment includes urinary albumin-to-creatinine ratio (UACR), estimated GFR calculations, and exclusion of alternative etiologies via serology and imaging when indicated. Serial monitoring is vital for tracking disease progression and therapeutic response.

Treatment & Management

The cornerstone of DKD management is multifactorial risk reduction, including intensive glycemic control, RAAS inhibition (ACE inhibitors or ARBs), blood pressure management, and lifestyle modification. Recently, sodium-glucose co-transporter-2 (SGLT2) inhibitors and MRAs such as finerenone and esaxerenone have been incorporated into treatment paradigms. Esaxerenone, administered orally, demonstrates potent mineralocorticoid receptor blockade with a lower risk of hyperkalemia compared to steroidal MRAs, making it suitable for long-term use in DKD.

Recent Advances / Emerging Therapies

Recent randomized controlled trials and observational studies have established the efficacy of esaxerenone in reducing albuminuria and preserving renal function over prolonged follow-up periods. The ESAX-DN trial and subsequent real-world studies from Japan demonstrated significant reductions in UACR and slower eGFR decline among DKD patients, with a manageable safety profile. Emerging evidence suggests esaxerenone may also confer cardiovascular protection, though long-term outcome data are still evolving. Combination therapy with SGLT2 inhibitors or GLP-1 receptor agonists may further enhance renoprotection.

Guideline Recommendations

Recent clinical guidelines, including those from the Japanese Society of Nephrology and Diabetes, endorse the use of selective MRAs like esaxerenone in DKD patients with persistent albuminuria despite optimized RAAS blockade and blood pressure control. Cautious titration and regular monitoring of serum potassium and renal function are recommended to mitigate potential adverse effects. Esaxerenone represents a promising adjunct to established therapies, especially in patients at high risk for progression or with contraindications to other agents.

Conclusion

Esaxerenone has emerged as a valuable addition to the therapeutic armamentarium for diabetic kidney disease, offering sustained antiproteinuric effects and renoprotection with an acceptable safety profile. Its selective mechanism of action addresses key pathophysiological pathways in DKD, and recent clinical evidence supports its long-term effectiveness. Ongoing studies will further elucidate its role in combination regimens and its impact on hard renal and cardiovascular endpoints. For clinicians managing DKD, esaxerenone provides an evidence-based option to improve patient outcomes and slow the inexorable progression to ESRD.